Loading stock data…
AMLX
$16.01+0.01 (+0.06%)
Market ClosedLast close May 1
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amylyx Pharmaceuticals, Inc. in the Healthcare sector is trading at $16.01. The stock is currently near its 52-week high of $18.61, remaining 22.4% above its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why AMLX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$16.01
Potential Upside
5%
Whystock Fair Value$16.81
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$23.30+45.5%
Range$19.00 – $34.00
Fundamentals
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigation...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.94B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-60.28%
Volume
Today's trading volume
721,795
Recent News
Amylyx Pharmaceuticals Sets Up Q3 Phase 3 Avexitide Data Readout, Eyes Potential 2027 Launch
Amylyx Pharmaceuticals (NASDAQ:AMLX) is entering what it described as a pivotal year for its lead program, avexitide, with Phase 3 data expected in the third quarter and preparations underway for a potential commercial launch in 2027, Chief Financial Officer Jim Frates said during a Needham investor
Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds. On March 24, Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) stated that the final subject in the Phase 3 Lucidity clinical study of avexitide had been randomised and dosed. This 16-week multicentred, randomised, double-blind, placebo-controlled study examines the […]
Is LUCIDITY Trial Completion in Post-Bariatric Hypoglycemia Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)?
Amylyx Pharmaceuticals recently reported that it has randomized and dosed the last participant in LUCIDITY, its pivotal Phase 3 trial of avexitide for post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery, marking full enrollment in this 16-week, double-blind, placebo-controlled study. This milestone moves Amylyx closer to potentially filing for approval of a first-in-class GLP-1 receptor antagonist in a condition with no FDA-approved therapies, informed by earlier trials...
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Amid Economic Data Releases
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) retreated by 0.2% and the activel
Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at Leerink Conf.
Amylyx Pharmaceuticals (NASDAQ:AMLX) co-CEO Justin Klee discussed the company’s lead endocrine program, avexitide, and provided updates on its pivotal LUCIDITY trial during a conversation at day two of the Leerink Partners Conference. Avexitide mechanism and the unmet need in post-bariatric hypogly